Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 6/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 9/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478326 | 1.00 | ADK (0.34) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL27178373 | 0.86 | METTL3 (0.42) | METTL3RAPGEF3 | |
| SCHEMBL22002064 | 0.84 | PRMT5 (0.35) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29478330 | 0.78 | ADK (0.52) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL24293819 | 0.78 | ADK (0.52) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL24293844 | 0.78 | ADK (0.52) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL29478311 | 0.78 | ADK (0.52) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL29478332 | 0.78 | ADK (0.52) | ADKMETTL3RAPGEF3PI4KAPI4K2B | |
| SCHEMBL22002162 | 0.76 | PRMT5 (0.37) | — | |
| SCHEMBL29478315 | 0.76 | PRMT5 (0.31) | METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101589-A1 | INHIBITORS OF METTL3 | EVOTEC INTERNATIONAL GMBH (DE) | 2024-03-28 | — | — | US | disclosed |
| WO-2022074391-A1 | COMPOUNDS INHIBITORS OF METTL3 | STORM THERAPEUTICS LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022074391-A1 | COMPOUNDS INHIBITORS OF METTL3 | STORM THERAPEUTICS LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101589-A1 | INHIBITORS OF METTL3 | METTL3, TPMT, DIMT1 | ADK 157/4885METTL3 1/4885RAPGEF3 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.